Clonal Hematopoiesis of Indeterminate Potential in Heart Failure.

Condition(s) studied

Investigational drug(s) / intervention(s)

Clinical and instrumental examination: Each patient, consecutively afferent to the SC Cardiologia I of the ASST-PG23 in Bergamo with the diagnosis of acute or chronic HF, at enrollment will undergo to routine clinical and instrumental examination.

Study summary

This study is part of the Rico Macro-Project, a multidisciplinary research program promoted by FROM in collaboration with the ASST-PG23 and ATS Bergamo, aiming to investigate the role of clonal hematopoiesis on inflammation, studying in depth the mechanisms underlying the inflammatory process to determine their correlation with some important pathologies in different clinical fields (Hematology, Cardiology, Neurology, Pneumology, Gastroenterology, and Diabetology, etc.). In this context, the prospective observational study RICO-HF is developed.

The RICO HF is the first project focused on CHIP and inflammation in the area of Cardiology, specifically in HF.

Eligibility

Primary outcome measure(s)

• Evaluate the prevalence of CHIP in patients with a diagnosis of acute HF according to the value of LVEF>50% (HFpEF) or ≤50% (HFmrEF/HFrEF) at the time of hospitalization. — At diagnosis during the baseline
  Obtained by medical health records

Trial sites (2)

More FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS trials in Italy

Other trials for the same condition